Alzheimer's Drugs Don't Work, Says Largest-Ever Review: What to Do Instead

# Alzheimer's Drugs Don't Work, Says Largest-Ever Review: What to Do Instead

> **Quick answer:** A landmark Cochrane review of 17 clinical trials and 20,342 participants published in April 2026 found that drugs targeting amyloid plaques in the brain — including Leqembi and Kisunla — show no clinically meaningful effect on memory decline or dementia severity. They also increase the risk of brain swelling and bleeding. Researchers now say future Alzheimer's research must move beyond amyloid entirely — and the best evidence points to lifestyle factors and even personality traits as more meaningful levers of protection.

Alzheimer's drugs don't work. That's the stark, peer-reviewed conclusion of the most comprehensive evidence review ever conducted on anti-amyloid therapies — the drug class that has consumed billions in research funding and was supposed to be medicine's best shot at stopping dementia. If you or someone you love is counting on these medications, this is information you cannot afford to miss.

This article is for informational purposes only and does not replace professional medical advice. Consult a healthcare provider for medical concerns.

## The Cochrane Review: What Was Found and Why It Matters

The Cochrane Collaboration — widely regarded as the gold standard in evidence-based medicine — released a bombshell review in April 2026 that synthesized results from **17 clinical trials involving 20,342 participants**. All trials focused on people with mild cognitive impairment or early-stage Alzheimer's dementia.